-

Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day

  • Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness on a global scale.
  • Selected candidates will be given a global platform to champion the diabetes community while starring in Dexcom’s 2025 World Diabetes Day campaign.

SAN DIEGO & BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada in search of the next diabetes advocates. Those selected will experience a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale this World Diabetes Day (Nov. 14) and beyond.

Now through Sept. 19, people from 2 years and older living with all types of diabetes and prediabetes – including Dexcom Warriors* and Stelo ambassadors – can apply at Dexcom.com/WorldDiabetesDay. Those selected will embody strength, advocacy and pride living with diabetes.

“We’ve long believed that real people with diabetes should be the voice of our company, and we’ve fostered that belief through our global Dexcom Warrior and Stelo Ambassador communities,” said Anne Santoro, senior vice president, product marketing at Dexcom. “Now, we’re giving these communities – and anyone living with diabetes who’s passionate about raising awareness – a chance to share their voice on a global stage.”

Those selected will receive an invite to participate in a photoshoot in Los Angeles to have their unique and inspiring story featured in Dexcom’s 2025 World Diabetes Day campaign. They’ll also have ongoing support from Dexcom over the next year to attend events, connect with the diabetes community and continue to advocate for diabetes awareness.

“I never sought to be the face of diabetes advocacy – I just wanted to share my story and hope that it would connect with people,” said Nick Jonas, American multi-platinum recording artist, songwriter, actor and philanthropist. “Over the years, I’ve learned that using our voices to spread messages of support, hope and perseverance can have a major impact on people’s lives, so I’m proud to support this open call and see Dexcom empower people with diabetes to do even more incredible work in their communities.”

To nominate yourself or someone you know, visit Dexcom.com/WorldDiabetesDay. Nominations close Sept. 19 at 12 p.m. PDT.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

*

Dexcom G-Series products are indicated for individuals with T1, T2 or Gestational Diabetes ages 2 years and older

Stelo is cleared by the FDA for adults not on insulin who are 18 or older* in the United States

 

Contacts

Media Contact
James McIntosh
mediarelations@dexcom.com

Investor Contact
Sean Christensen
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Media Contact
James McIntosh
mediarelations@dexcom.com

Investor Contact
Sean Christensen
sean.christensen@dexcom.com

More News From DexCom, Inc.

Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now available in Belgium, Germany, the Kingdom of Saudi Arabia, the Netherlands, and Spain with further EMEA country launches planned for 2026. Guided directly by H...

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM sy...

Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as...
Back to Newsroom